GEN-003: Phase II started

Genocea began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3 doses of 30 or 60 Ug intramuscular GEN-003 containing 25, 50 or 75 Ug Matrix M given 21 days apart in about 300 pati...